Embecta Corp. EMBC

Company Overview

Embecta Corp. is a medical technology and diabetes care company focused primarily on the design, development, manufacturing, and commercialization of insulin delivery products for people living with diabetes. The company operates within the global healthcare and medical devices industries, with a concentration on disposable diabetes management products such as insulin syringes, pen needles, and related injection devices. Embecta was established as an independent public company in 2022 following its spin-off from Becton, Dickinson and Company (BD), which historically operated the business as part of BD’s diabetes care segment.

The company’s primary revenue drivers are its broad portfolio of pen needles, conventional insulin syringes, and safety-engineered injection products sold to retail pharmacies, wholesalers, hospitals, and healthcare providers. Embecta serves both developed and emerging healthcare markets, benefiting from long-standing relationships with healthcare distributors and clinicians. Its strategic positioning is supported by its scale in insulin injection devices, a globally recognized manufacturing and distribution infrastructure inherited from BD, and a large installed customer base across diabetes care channels.